Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside -- Ignore unavailable to you. Want to Upgrade?

To: Richard Birk who wrote (479)	1/28/1999 8:56:00 AM
From: Yo Yo	Read Replies (1) \| Respond to of 492

Any mention of how the automated disk machine is doing? Looking through this qtrs numbers... Disks sold per machine in use dropped a bit, of course, machine sales are dropping too. Looks like market may be saturating for the short term in Vet. I would guess more tests and eventual human market use will drive growth. Profitability will be driven by automated disk machine. Interestingly, HMGN, who make the competing Analyst(R) machine which does much better in human market, just reported a bang up quarter, based heavily on profitability of disk sales to the human market. They are attempting to compete in vet market too. Frankly, I think these two companies ought to merge. HMGN makes the reagants, has good human installed base, profitable disk business. ABAX has a more modern machine and is kicking butt in vet market. Unfortunately, I would bet CEO egos would prevent such a deal. HMGN is a play toy for the CEO who is also head of Biochem Dept at Boston Univ., he's pretty well connected. I currently own some HMGN, still waiting for ABAX to show signs of profitability. Yo Yo